Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma (Q44004521)

28 November 2017

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma (English)

1 reference

28 November 2017

0 references

1 reference

dasatinib monohydrate

1 reference

1 reference

7

1 reference

28 November 2017

Enrique Colado

9

0 references

Patricia Maiso

object named as

Patricia Maiso

2

0 references

Mercedes Garayoa

object named as

Mercedes Garayoa

5

0 references

Enrique M Ocio

object named as

Enrique M Ocio

12

0 references

author name string

Edvan de Queiroz Crusoe

1

1 reference

28 November 2017

Diego Fernandez-Lazaro

3

1 reference

28 November 2017

Laura San-Segundo

4

1 reference

28 November 2017

Antonio Garcia-Gomez

6

1 reference

28 November 2017

Manuel Delgado

8

1 reference

28 November 2017

Jesus Martin-Sanchez

10

1 reference

28 November 2017

Francis Y Lee

11

1 reference

28 November 2017

language of work or name

1 reference

1 July 2011

1 reference

28 November 2017

1 reference

28 November 2017

91

1 reference

28 November 2017

2

1 reference

28 November 2017

257-269

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

28 November 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

New therapies in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Multifunctional role of Erk5 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

A phase II trial of imatinib in patients with refractory/relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

myc function and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

Expression and function of chemokine receptors in human multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1287-Z

10.1007/S00277-011-1287-Z

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference